News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PHT Corporation SitePad® Used To Collect Electronic Data For Celgene Corporation (CELG)'s Recently Approved OTEZLA (apremilast) Tablets


5/1/2014 2:39:45 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON & GENEVA--(BUSINESS WIRE)--Celgene Corporation used the PHT Corporation SitePad® System to collect primary and secondary endpoints for studies of its Otezla (apremilast) drug which the FDA approved in March 2014 to treat adults with active psoriatic arthritis (PsA).

PHT is the leading provider of technologies used to collect patient-driven eData for clinical research. The PHT SitePad System includes a large-screen mobile tablet for capturing study-specific clinician and patient assessments at the investigative site. Real-time access to all the data collected is available in StudyWorks™, the PHT online portal for data review and management. Using the SitePad System helps to increase the quality of the data collected, the time to database lock and reduces monitoring time and costs.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES